• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者报告的肾细胞癌诊断、管理及负担体验:来自43个国家的全球患者调查结果

Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.

作者信息

Giles Rachel, Maskens Deborah, Bick Robert, Martinez Robin, Packer Malcolm, Heng Daniel, Larkin James, Bex Axel, Jewett Michael, Jonasch Eric, MacLennan Sara

机构信息

International Kidney Cancer Coalition, Amsterdam-Duivendrecht, The Netherlands.

Kidney Cancer Canada, Mississauga, ON, Canada.

出版信息

Eur Urol Open Sci. 2022 Jan 17;37:3-6. doi: 10.1016/j.euros.2021.12.003. eCollection 2022 Mar.

DOI:10.1016/j.euros.2021.12.003
PMID:35243386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8883191/
Abstract

UNLABELLED

The International Kidney Cancer Coalition (IKCC) is a federation of 46 affiliated patient organisations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. A large-scale global survey of patients with renal cell carcinoma (RCC) to capture real-world experiences has never been undertaken. The 35-question survey was designed to identify geographic variations in patient education, experience, awareness, access to care, best practices, quality of life, and unmet psychosocial needs. A total of 1983 responses were recorded from 43 countries in 14 languages. Analysis revealed key findings. (1) At diagnosis, 43% of all respondents had no understanding of their RCC subtype. (2) Shared decision-making remains aspirational: globally, 29% of all patients reported no involvement in their treatment decision, responding "My doctor decided for me". (3) While 96% of respondents reported psychosocial impacts, surprisingly, only 50% disclosed them to their health care team. (4) Lastly, 70% of patients were not asked to participate in a clinical trial, although 90% indicated they would be interested. The survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. The data point to actionable deficits in the fields of clinical trials, psychosocial support, and shared decision-making.

PATIENT SUMMARY

In this brief report, we highlight the key results from the first large-scale global survey of patients with kidney cancer to capture real-world experiences. This survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. We conclude that there is a need for improvement in the fields of clinical trials, psychosocial support, and shared decision-making.

摘要

未标注

国际肾癌联盟(IKCC)是一个由46个附属患者组织组成的联盟,代表着全球120万患者,致力于减轻全球肾癌负担。此前从未对肾细胞癌(RCC)患者进行过大规模的全球调查以了解实际情况。这项包含35个问题的调查旨在确定患者教育、经历、认知、医疗服务可及性、最佳实践、生活质量以及未满足的心理社会需求方面的地域差异。共收到来自43个国家、14种语言的1983份回复。分析得出了关键结果。(1)在确诊时,43%的受访者不了解自己的RCC亚型。(2)共同决策仍有待实现:在全球范围内,29%的患者表示未参与治疗决策,回答是“我的医生替我做了决定”。(3)虽然96%的受访者报告了心理社会影响,但令人惊讶的是,只有50%向其医疗团队透露了这些情况。(4)最后,70%的患者未被邀请参加临床试验,尽管90%表示他们会感兴趣。该调查反映了不同临床场景下患者的观点,在这些场景中有不同的治疗选择。这些数据指出了临床试验、心理社会支持和共同决策领域中可采取行动加以弥补的不足。

患者总结

在本简要报告中,我们突出了首次针对肾癌患者进行的大规模全球调查的关键结果,以了解实际情况。该调查反映了不同临床场景下患者的观点,在这些场景中有不同的治疗选择。我们得出结论,临床试验、心理社会支持和共同决策领域需要改进。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/208c/8883191/4fb2ada06ae4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/208c/8883191/4fb2ada06ae4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/208c/8883191/4fb2ada06ae4/gr1.jpg

相似文献

1
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.患者报告的肾细胞癌诊断、管理及负担体验:来自43个国家的全球患者调查结果
Eur Urol Open Sci. 2022 Jan 17;37:3-6. doi: 10.1016/j.euros.2021.12.003. eCollection 2022 Mar.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.不同种族文化群体成年癌症患者的姑息治疗体验:一项定性系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):99-111. doi: 10.11124/jbisrir-2015-1809.
4
A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.对所有医疗环境中共同决策的内部和外部影响进行的定性系统评价。
JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432.
5
6
Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid.癌症转变为慢性病时的决策制定:基于网络的甲状腺髓样癌患者决策辅助工具的需求评估
JMIR Form Res. 2021 Jul 16;5(7):e27484. doi: 10.2196/27484.
7
Tuberculosis结核病
8
9
Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.促进和支持社区中患有慢性身体疾病的成年人进行自我管理:对医患互动的有效性和意义的系统评价。
JBI Libr Syst Rev. 2009;7(13):492-582. doi: 10.11124/01938924-200907130-00001.
10
Patient advocate perspectives on involvement in HTA: an international snapshot.患者权益倡导者对参与卫生技术评估的看法:国际概览
Res Involv Engagem. 2017 Jan 10;3:2. doi: 10.1186/s40900-016-0052-9. eCollection 2017.

引用本文的文献

1
Wellbeing status and priority concerns of patients with advanced renal cell carcinoma: results of the EONS PROMs project international online survey.晚期肾细胞癌患者的健康状况及优先关注问题:EONS PROMs项目国际在线调查结果
Support Care Cancer. 2025 Jun 3;33(6):531. doi: 10.1007/s00520-025-09585-5.
2
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.一线晚期肾细胞癌的健康相关生活质量概况及临床结局:基于CheckMate 9ER研究的建模分析
ESMO Open. 2025 Jun;10(6):105115. doi: 10.1016/j.esmoop.2025.105115. Epub 2025 May 23.
3

本文引用的文献

1
Self-reported quality of life as a predictor of mortality in renal cell carcinoma.自我报告的生活质量作为肾细胞癌死亡率的预测指标。
Cancer. 2022 Feb 1;128(3):479-486. doi: 10.1002/cncr.33956. Epub 2021 Oct 5.
2
Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries.56 个国家的医疗支出与肾癌死亡率与发病率比值的变化趋势。
Sci Rep. 2021 Jan 14;11(1):1479. doi: 10.1038/s41598-020-79367-y.
3
Cancer Statistics, 2021.癌症统计数据,2021.
Development of a Patient Decision Aid for cT1 Renal Masses: A User-Centered Mixed-Methods Study.
cT1期肾肿块患者决策辅助工具的开发:一项以用户为中心的混合方法研究。
Urol Pract. 2025 Sep;12(5):568-577. doi: 10.1097/UPJ.0000000000000830. Epub 2025 May 15.
4
Cross-sectional study of therapy-related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan.日本转移性肾细胞癌患者和医生的治疗相关期望/担忧的横断面研究。
Cancer Med. 2024 Jun;13(11):e7196. doi: 10.1002/cam4.7196.
5
The evolving management of small renal masses.小肾肿瘤的不断演变的治疗策略。
Nat Rev Urol. 2024 Jul;21(7):406-421. doi: 10.1038/s41585-023-00848-6. Epub 2024 Feb 16.
6
Patient experience of follow-up after surgery for kidney cancer: a focus group study.肾细胞癌术后随访患者体验的焦点小组研究。
BJU Int. 2023 Jul;132(1):47-55. doi: 10.1111/bju.15982. Epub 2023 Feb 22.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
4
COVID-19 and financial toxicity in patients with renal cell carcinoma.COVID-19 与肾细胞癌患者的财务毒性。
World J Urol. 2021 Jul;39(7):2559-2565. doi: 10.1007/s00345-020-03476-6. Epub 2020 Oct 22.
5
Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma.局限性肾细胞癌患者对癌症复发的恐惧
JCO Oncol Pract. 2020 Nov;16(11):e1264-e1271. doi: 10.1200/OP.20.00105. Epub 2020 Sep 18.
6
Distress in patients with renal cell carcinoma: a curious gap in knowledge.肾细胞癌患者的痛苦:一个奇怪的知识空白。
BJU Int. 2019 Feb;123(2):208-209. doi: 10.1111/bju.14564. Epub 2018 Oct 24.